Old API Wind-down Ltd. Stock

Stocks

ARLZQ

CA03852X1006

Pharmaceuticals

OTC Markets Traded
Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Old API Wind-down Ltd. -.--% -
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Old API Wind-down Ltd.

Market Cap 87.35K 75.8K 69.87K 65.47K 122K 8.36M 125K 834K 323K 4.03M 328K 321K 14.02M P/E Ratio 2016
-2.53x
P/E Ratio 2017 -0.75x
Enterprise Value 246M 213M 197M 184M 344M 23.53B 351M 2.34B 908M 11.34B 923M 903M 39.44B EV / Sales 2016
9.18x
EV / Sales 2017 3.22x
Free-Float
100%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
-0.75%+2.64%+43.02%+160.79% 1,035B
+0.15%+2.80%+52.74%+49.64% 574B
+0.67%+0.48%+18.65%+65.77% 397B
+0.06%+0.77%+21.19%+15.95% 324B
-0.34%-2.08%+23.03%+14.71% 281B
+0.65%+3.66%+24.71%+34.63% 278B
+0.31%+4.21%-45.41%-48.18% 193B
-0.46%+1.86%+19.77%+63.82% 191B
-0.58%-2.23%+12.70%+62.19% 156B
Average +0.01%+1.51%+18.93%+46.59% 342.99B
Weighted average by Cap. -0.12%+2.39%+28.98%+73.65%

Financials

2016 2017
Net sales 54.27M 47.1M 43.41M 40.68M 76M 5.2B 77.58M 518M 200M 2.5B 204M 199M 8.71B 106M 91.94M 84.75M 79.41M 148M 10.14B 151M 1.01B 391M 4.89B 398M 389M 17B
Net income -103M -89.36M -82.37M -77.19M -144M -9.86B -147M -983M -380M -4.75B -387M -378M -16.53B -125M -109M -100M -93.84M -175M -11.99B -179M -1.19B -463M -5.78B -470M -460M -20.09B
Net Debt 209M 182M 168M 157M 293M 20.06B 299M 2B 774M 9.67B 786M 770M 33.62B 246M 213M 197M 184M 344M 23.52B 351M 2.34B 908M 11.34B 922M 902M 39.42B
Logo Old API Wind-down Ltd.
Old API Wind-Down Ltd, formerly Aralez Pharmaceuticals Inc., is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).
Employees
-
  1. Stock Market
  2. Stocks
  3. ARLZQ Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!